Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355570 | 0.96 | OPRM1 (0.56) | OPRM1OPRL1DPP4CTSLCTSB | |
| Methyl Alcohol SCHEMBL10438266 | 0.94 | OPRM1 (0.55) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL9131464 | 0.94 | CTSL (0.56) | OPRM1OPRL1DPP4CTSLCTSB | |
| Ammonia Solution, Strong SCHEMBL5339394 | 0.94 | OPRM1 (0.54) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL61112 | 0.94 | CTSL (0.56) | OPRM1OPRL1DPP4CTSLCTSB | |
| Bicarbonate SCHEMBL5176713 | 0.92 | OPRM1 (0.50) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL6469380 | 0.91 | OPRM1 (0.59) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL19067383 | 0.91 | OPRM1 (0.49) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL24752799 | 0.89 | DPP4 (0.51) | OPRM1OPRL1DPP4CTSLCTSB | |
| SCHEMBL29081313 | 0.89 | ALDH1A1 (0.50) | OPRM1OPRL1DPP4CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683493-B | Electron-rich conjugated diene compound, preparation method and application | 四川大学 | 2022-06-10 | — | — | CN | claimed |
| EP-2139854-A2 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | SCHERING CORPORATION (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2009008913-A2 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | SCHERING CORPORATION (US) | 2009-01-15 | — | — | WO | claimed |
| CN-113905785-B | Cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| EP-3354639-B1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | NIHON MEDIPHYSICS CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| CN-117203202-A | Quinoxaline derivative and use thereof | 黑钻治疗公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023158725-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | LUCY THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| CN-115820071-B | Corrosion-resistant coating and preparation method thereof | 山东奔腾漆业股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2023147328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
| EP-2952503-A1 | HIV REPLICATION INHIBITOR | Shionogi & Co., Ltd. (JP) | 2015-12-09 | — | — | EP | disclosed |
| EP-2349982-B1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA S R L (IT) | 2015-08-05 | — | — | EP | disclosed |
| WO-2012150220-A1 | RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| EP-2139854-A2 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | SCHERING CORPORATION (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2009008913-A2 | P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE | SCHERING CORPORATION (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-0862464-A4 | AMINO ACID ANALOGS FOR TUMOR IMAGING | UNIV EMORY (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-0862464-A1 | AMINO ACID ANALOGS FOR TUMOR IMAGING | EMORY UNIVERSITY (US) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAPK7, MAPK14 | OPRM1 2646/4885OPRL1 4113/4885DPP4 701/4885 |
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | RTF2, REV1, PCNA | OPRM1 1163/4885OPRL1 2491/4885DPP4 2018/4885 |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | OPRM1 1548/4885OPRL1 2430/4885DPP4 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.